Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies
In-Person Event
Oct 17 - 20, 2018
New York City, New York, USA
OVERVIEW
18th Annual Lymphoma & Myeloma: An International Congress on Hematologic Malignancies is organized by Imedex and will be held from Oct 17 - 20, 2018 at Sheraton New York Times Square Hotel, New York City, New York, United States of America.
The target audience for this medical event is domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. This CME Conference has been approved for a maximum of 27.75 AMA PRA Category 1 Credits
Course Objectives are :
• Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignancies
• Define mechanisms of action of current and emerging agents for hematologic malignancies
• Assess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignancies Formulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)
• Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignancies
• Evaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignancies
Speakers:
Morton Coleman, MD, Weill Cornell Medicine, Congress Chair, John P. Leonard, MD, Weill Cornell Medicine, Co-Chair, Ruben Niesvizky, MD, Weill Cornell Medicine, Co-Chair, Richard R. Furman, MD, Weill Cornell Medicine, Co-Chair
Time: 8:00 am to 4:00 pm
Additional details will be posted as soon as they are available.
The target audience for this medical event is domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies. This CME Conference has been approved for a maximum of 27.75 AMA PRA Category 1 Credits
Course Objectives are :
• Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignancies
• Define mechanisms of action of current and emerging agents for hematologic malignancies
• Assess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignancies Formulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)
• Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignancies
• Evaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignancies
Speakers:
Morton Coleman, MD, Weill Cornell Medicine, Congress Chair, John P. Leonard, MD, Weill Cornell Medicine, Co-Chair, Ruben Niesvizky, MD, Weill Cornell Medicine, Co-Chair, Richard R. Furman, MD, Weill Cornell Medicine, Co-Chair
Time: 8:00 am to 4:00 pm
Additional details will be posted as soon as they are available.
KEY DATES
17 Oct, 2018
Event Start Date
20 Oct, 2018
Event End Date
SPECIALITIES
Hematology Blood and Marrow TransplantOncologySUGGESTED HOTELS
CONFERENCE VENUE
Sheraton New York Times Square HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links